This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Treatment

Authoring team

Treatment of acute immune TTP is with both:

  • Urgent plasma exchange (PEX) (1,2)
    • prophylactic plasma infusion remains the mainstay for treatment of hereditary TTP resulting from mutations in ADAMTS13 (2)
    • therapeutic plasma exchange (TPE) is the treatment of choice for acquired TTP due to autoantibodies against ADAMTS13 (2)
  • Immunosuppression – to switch off the immune system response destroying the ADAMTS13 in the Immunosuppression is with high dose steroids initially and Rituximab.

Early administration of rituximab during acute episodes reduces time to remission and rituximab should be started within 72 hours of diagnosis. On average, inpatient stay is 14 days and treatment continues as an outpatient, aiming to normalise ADAMTS13 activity (1)

Reference:

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.